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Angiotensin converting enzyme inhibition improves glomerular size-
selectivity in IgA nephropathy. Clearances of uncharged dextrans of
broad size distribution were used to evaluate the effects of a 30 day
course of enalapril on glomerular barrier function in 10 patients with
IgA nephropathy and proteinuria (from 1.4 to 5.6 g/day). Dextran
clearance experiments were repeated three times: before enalapril
therapy, after 30 days of enalapril and again 30 days after enalapril
withdrawal. GFR, but not RPF, was significantly reduced by enalapril
(basal 38.3 11.9, enalapnl 30.2 12.6 ml/min/1.73 m2) and returned
to basal values after enalapril withdrawal. Urinary protein excretion
and fractional clearance of albumin were both significantly reduced by
enalapril (basal 2.3 1.1 g/day and 102 90 x enalapril 1.2 0.6
g/day and 51 23 x respectively) and returned to basal values
after enalapril withdrawal. Transglomerular passage of large dextrans
(radii 54 to 62 A), but not of lower size (26 to 42 A) were significantly
lowered by enalapril. When enalapril was withdrawn the dextran-
sieving profile returned comparable to the baseline levels. A theoretical
analysis of dextran-sieving profiles indicated that enalapril lowered the
radius of largest membrane pores. This effect was independent from
glomerular hemodynamic changes. We conclude that angiotensin con-
verting enzyme inhibitors (CEI) in humans with IgA nephropathy
reduces urinary protein excretion by a primary action on the intrinsic
glomerular membrane properties enhancing barrier size-selective func-
tion. The hypofiltration associated with enalapril therapy in these
patients, which was eliminated by its withdrawal, has to be taken into
account as a possible undesired effect of CEI in long-term treatment.
Angiotensin-converting enzyme inhibitors (CE!) reduce pro-
teinuria in various experimental and human glomerular dis-
eases. Data are conflicting on the extent of this effect and on
whether it applies to all forms of glomerular injury involving
increased glomerular permeability to proteins. Data on the
favorable effects of CE! on proteinuria have mainly been
obtained in rats with reduction of renal mass and streptozotocin
diabetes [1, 2] and in diabetes mellitus in humans [3—5]. Of
interest in both laboratory and human studies the reduction of
glomerular permeability to proteins induced by CE! is associ-
ated with an enhancement of glomerular barrier size-selectivity
[5, 6]. However, so far no controlled information is available on
the effect of CEI on other forms of glomerular damage, partic-
ularly in proliferative glomerulonephritis.
One of the most widespread forms of human proliferative
glomerulonephritis is IgA nephritis, a disease of recurrent
hematuria and glomerular deposits of immunoglobulin and
complement in the mesangial region. Most of these patients
have proteinuria, and recently a subset of patients has been
identified in which the disease may rapidly progress to terminal
renal failure [7]. Since the most proteinuric forms of !gA
glomerulonephritis tend to have a severely progressive course,
any attempt to reduce proteinuria is of primary clinical rele-
vance.
The present study was designed to explore the effects of CE!
on glomerular function and size-selective properties in patients
with IgA glomerulonephritis. Glomerular function and size-
selectivity were explored by a solute clearance technique.
Renal clearance studies were done before and after one month
of treatment with CE!, and were repeated in all patients one
month after withdrawal of CEI therapy.
Methods
Patient population
Ten male patients with biopsy-proven IgA mesangial
nephropathy were studied. Admission criteria to the study
were: clinical proteinuria (>1 g/day) on three consecutive
occasions in the last two months before entry into the study;
normal or moderately reduced renal function (creatinine clear-
ance >30 mI/mm); no previous or concomitant immunosuppres-
sive treatment; no treatment with NSA!D or CE! in the three
months before selection. Informed consent was obtained before
entry into the study.
The patients' average age was 34 years (range 25 to 58). At
admission four patients were normotensive, blood pressure
(BP) less than 140/85 mm Hg, five patients were on antihyper-
tensive treatment with beta blocker (atenolol < 100 mg/day),
one patient was on calcium antagonist (nifedipine 20 mg/day)
therapy plus diuretic (furosemide 25 mg/day). Patients on
antihypertensive therapy had BP values less than 150/95 mm
Hg.
Study protocol
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The effect of a CE!, enalapril (Merk Sharp & Dome Italia,
Rome, !taly), on glomerular function was evaluated using a
sequential study protocol. A first evaluation of glomerular
function was done before enalapril treatment by measurement
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of inulin, para-aminohippurate (PAH) and neutral dextran clear-
ance. Starting right after the basal evaluation patients received
enalapril for one month, at the end of which the clearance study
was repeated. A third clearance study was done one month
after enalapril withdrawal. These three clearance studies are
referred to as basal, enalapril and enalapril withdrawal, respec-
tively.
Enalapril therapy was started at a dose of 5 mg/day, increased
if necessary to a maximum of 15 mg/day over the next few days
to maintain systolic BP between 100 and 150 mm Hg and
diastolic BP between 70 and 95 mm Hg. During treatment with
CEI other antihypertensive drugs were discontinued. When
CEI treatment was completed patients were returned to their
original antihypertensive therapy if previously adopted.
Clearance studies
Inulin, PAH and neutral dextran clearances were measured
as previously described [8] under a steady state of diuresis
induced by oral water loading; exactly the same procedure was
followed for each patient during the three clearance studies. A
priming infusion containing 10% inulin, 20% PAH and 10%
Dextran 40 (Rheomacrodex, Pharmacia, Uppsala, Sweden, 130
mg/kg) was infused, followed by continuous administration of
inulin and PAH to maintain constant plasma concentrations of
approximately 15 and 1.5 mg/dl, respectively.
After an equilibration period of about 60 minutes, three
exactly-timed urine collections of about 30 minutes were made
by spontaneous voiding. Blood was sampled at the beginning
and end of each clearance period for assays of inulin and PAH.
From urine and plasma samples obtained during the first
clearance period the concentrations of neutral dextrans of
graded sizes and albumin were also determined. Fractional
clearance of these test macromolecules was computed as:
(U/P)m/(UIP)IN, where (U/P)m and (U/P)JN are the urine to
plasma concentration ratios of the test macromolecule and
inulin, respectively.
GFR and RPF were calculated respectively as the average
inulin and PAH clearance for the three timed collection periods,
corrected for body surface area. For RPF calculation an as-
sumed PAH extraction ratio of 0.7 was also adopted to account
for the depression of renal PAH extraction observed in patients
with proteinuric glomerular disease and reduced GFR [9].
Laboratory methods
Inulin and PAH concentrations in plasma and urine samples
were determined using methods previously described [10, 111.
Graded size dextran molecules and inulin in the same samples
were separated by gel permeation chromatography on a Ultro-
gel AcA 44 column (1.6 x 95 cm, LKB, Uppsala, Sweden).
Column calibration was performed periodically using dextran
fractions of known molecular weight (Dextran Tb, T40 and
T70, Pharmacia, Uppsala, Sweden) and inulin. Effective molec-
ular radius, r, for dextran molecules in eluted fractions was
calculated from the following linear relationship [12, 13] as a
function of molecular weight (MW):
r 0.33 x (MW)°463
Dextran and inulin were assayed in the eluted fractions using
the anthrone method of Scott and Melvin [14], with slight
modifications. Urine-to-plasma concentration ratios for inulin
were calculated from inulin concentrations in eluted fractions.
Albumin concentrations in plasma and urine samples were
determined using a radioimmunoassay (Diagnostic Products
Corporation, Los Angeles, California, USA). Protein concen-
tration in urine samples was determined by the Coomassie
blue-g dye binding method [15]. Other laboratory tests were
done with routine laboratory methods.
Theoretical analysis of glomerular ultrafiltration and solute
transport
To detect changes in membrane permeability properties
induced by the drug treatment we analyzed experimental ob-
servations of fractional clearance of test macromolecules using
a mathematical model of glomerular size-selectivity described
in detail previously [16, 173. This model permits a differentiation
between the effects of membrane permeability changes and
glomerular hemodynamic alterations on glomerular filtration of
neutral macromolecules. It considers the glomerular membrane
as perforated by cylindrical pores having a lognormal distribu-
tion of radii given by the following equation:
1 1 (ln(r) — in(u)\2g(r) = \/ r in(s) exp - in(s) )
This function is characterized by two parameters, u and s.
According to this distribution the mean value of in(r) is in(u),
and s is a measure of the spread of the distribution.
Beside these two pore-size distribution parameters the model
is based on another freely adjustable parameter, the ultrafiltra-
tion coefficient (Kf), which is the product of the hydraulic
membrane permeability and glomerular filtering surface area.
Assuming that the glomerular population is uniform in function,
K1 was calculated as extended to all glomeruli in both kidneys
by using a model of glomerular ultrafiltration [16, 181. The
intrinsic membrane permeability parameters were calculated by
non-linear regression fitting of experimental data obtained in
single patients during the three clearance studies [17].
Statistical analysis
All results are expressed as mean standard deviation (SD).
All data were subjected to one-way analysis of variance and
statistical significance of differences between measurements in
the three studies was assessed using the Tukey-Cicchetti test
for multiple comparisons. Urinary protein excretion rates and
albumin fractional clearances were log-transformed before sta-
tistical analysis. Statistical significance was defined asP < 0.05.
Results
Blood pressure
Mean systolic and diastolic BP recorded during the clearance
studies are reported in Table 1. Systolic and diastolic BP were
both slightly but significantly lower at the end of enalapril
treatment than during basal evaluation; after enalapril with-
drawal both systolic and diastolic BP returned to pre-CEI
values.
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Table 1. Clinical findings
Enalapril
Basal Enalapril withdrawal
Systolic BP 143 12 132 13 140 9
mm Hg
Diastolic BP 87 8 77 10b 85 6C
mm Hg
Serum 1.4 0.3 1.5 0.4 1.5 0.3
creatinine
mg/dl
Serum proteins 5.3 0.4 5.4 0.3 5.4 0.4
gidi
Renal function
No significant difference was observed in mean serum creat-
mine levels and in total serum proteins during the three clear-
ance studies (Table 1). The results of the renal hemodynamic
studies are represented in Figure 1. Basal GFR averaged 38.3
11.9 mllminll .73 m; by the end of enalapril treatment in all
patients but one, GFR showed a tendency to decline, averaging
30.2 12.6 mIIminIl.73 m2 (P < 0.01). When enalapril treat-
ment was withdrawn GFR rose again in all patients, returning
toward basal values averaging 37.8 11.2 ml/min!1.73 m2 (P <
0.01 vs. enalapril). Enalapril had no effect on RPF, averaging
501 129, 500 154 and 487 167 ml/min/l.73 m2, respec-
tively before, after CE! treatnent, and one month after CEI
withdrawal. Thus the reduction in GFR observed after enalapril
treatment, with constant RPF, resulted in a slight but significant
reduction in filtration fraction (Fig. 1).
Values of 24-hour urinary protein excretion, measured before
each clearance study, and albumin fractional clearance are
reported in Figure 2. Both parameters decreased significantly (P
< 0.01) with enalapril treatment, as compared to pre-CEI
values, and returned to basal values after withdrawal of the
drug. Sieving coefficients of neutral dextran molecules of
graded sizes (from 26 to 62 A) measured in basal conditions and
at the end of enalapril treatment are reported in Table 2 and in
Figure 3. Fractional clearance of small dextran molecules (< 42
A) was not significantly affected by the drug treatment. Sieving
coefficients of larger dextran molecules (radii from 44 to 50 A,
and from 54 to 62 A) were significantly lower after CE!
treatment (Fig. 3). Figure 4 compares fractional dextran clear-
ance values at the end of enalapril therapy with values one
month after enalapril withdrawal. Withdrawal of the CE! was
associated with significant elevation of sieving coefficients for
dextrans larger than 54 A returning almost to pre-treatment
values (Fig. 4, Table 2).
Theoretical analysis of glomerular dextran transport
Dextran sieving coefficients and renal hemodynamic param-
eters were used for the theoretical analysis of glomerular
size-selective function. This theoretical approach requires the
assumption of the value of Dp, the hydraulic pressure gradient
across the glomerular membrane, that can not be measured in
humans. To overcome this limitation, and in accordance with
previous studies [5, 12], several values of Dp below and above
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35 mm Hg have been assumed, that is, the values believed to
represent normal Dp in humans. In particular, since experimen-
tal studies indicate that Dp may be increased in some glomer-
ular disease models and that enalapril decreases Dp in this
conditions [1, 2, 19], values of Dp were assumed ranging from
30 to 45 mm Hg, to take into account these possibilities.
The results of the theoretical analysis are reported in Table 3.
Estimation of the ultrafiltration coefficient (Kf) showed that
when Dp was assumed to be lowered by enalapril (by about 5
mm Hg), Kf remained comparable for the three sequential
studies. On the other hand, when Dp was assumed to be
unaffected by the drug treatment calculated, Kf was signifi-
cantly lower after enalapril treatment as compared to basal and
P<0.01 p<0p1
Values are mean SD. Abbreviation is: BP, blood pressure.
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b P < 0.01 vs. Basal
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Fig. 1. Renal functional parameters measured before (basal), after
enalapril treatment (enalapril), and one month after enalapril with-
drawal (enalapril withdrawal). Abbreviations are: GFR, glomerular
filtration rate; RPF, renal plasma flow; F'F, filtration fraction.
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Table 2. Fractional clearance of neutral dextrans
Molecular radius (A) 26 28 30 32 34 36 38 40 42 44
Basal 0.773 0.673 0.544 0.435 0.333 0.245 0.181 0.13 0.09 0.066
Enalapril 0.808 0.656 0.522 0,391 0.287 0.207 0.148 0.104 0.071 0.048
P vs. Basal NS NS NS NS NS NS NS NS NS 0.05
Enalapril withdrawal 0.844 0.701 0.571 0.438 0,331 0.244 0.176 0.124 0.085 0.059
P vs. Enalapril NS NS NS NS
—_NS NS NS NS NS NS
Values are mean SD. Abbreviation NS is not significant.
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enalapril withdrawal values. As mentioned previously, techni-
cal limitations make it impossible to further investigate which of
these two parameters is reduced by the CE! and is indeed
responsible for the reduced GFR.
Considering the calculated membrane pore parameters pre-
viously defined, it appeared that both parameters u and s,
respectively a measure of the mean and the spread of the pore
radii distribution, were not sensitive to changes of assumed Dp
values. That membrane pore parameters are not importantly
affected by the value of Dp is in line with previous observations
[161. Statistical comparison of the average values of u and s,
calculated for the three clearance studies, indicated that both
parameters were not significantly affected by the drug treat-
ment. This is consistent with the experimental finding that
filtration of small dextrans (radii ranging from 26 to 42 A) were
not affected by the CE! therapy, since these molecules can pass
the glomerular membrane through pores whose radii are similar
to the average membrane pore size. The experimental observa-
tion that largest dextran molecules (radii ranging from 56 to 62
A) were significantly affected by the drug treatment suggests
that enalapril may induce changes in the dimension of few large
membrane pores. We therefore calculated the membrane pore
parameter r*(1%), as described in detail previously [171, that is,
the pore radius at which 1% of the filtrate volume is filtered by
pores with radii greater than r*(1%). As reported in Table 3,
r*(1%), independently of the Dp value adopted for the calcula-
tion, was significantly and uniformly reduced by enalapril
treatment of about 4 A. After enalapril withdrawal r*(1%) rose
again significantly, reaching values comparable to the basal
evaluation. Thus CE! therapy seems mainly to have modified
the radius of the largest membrane pores leaving the selective
small pores unaffected. This effect is independent of changes in
GFR determinants (Dp and/or Kf) but is intrinsic to the mem-
brane's permeability properties to macromolecules.
Discussion
In patients with IgA nephropathy participating in the present
study, enalapril slightly but significantly reduced systolic and
diastolic BP compared to pre-enalapril values or to values
recorded in the same patients one month after enalapril with-
drawal. Renal function changes associated with enalapril ther-
apy involved a statistically significant reduction in GFR (21%
on average) without significant changes in RPF.
Little data is available so far on the possibility that enalapril
selectively induces glomerular hypofiltration in humans. Previ-
ous studies in animals and humans did not show significant GFR
reduction associated with CE! treatment [1, 2, 5]. The fact that
in the present study enalapril therapy was associated with a
reduction in GFR but not in RPF suggests that the renal
hypofiltration was a consequence of changes in other determi-
nants of GFR. Beside RPF, GFR is regulated by the colloid
osmotic pressure in glomerular capillaries due to circulating
plasma proteins, by the transmembrane hydraulic pressure
difference (Dp) and by the ultrafiltration coefficient (Kf). Since
no significant differences were recorded in protein concentra-
tions in arterial plasma during the study, the fall in GFR must
depend upon changes in either Dp or Kf, or both. Direct
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Fig. 2. Urinary protein excretion and fractional clearance of albumin
and IgG measured before (basal), after enalapril treatment (enalapril)
and one month after enalapril withdrawal (enalapril withdrawal).
Remuzzi et a!: Enalapril in IgA nephropathy 1271
Table 2. Continued
46 48 50 52 54 56 58 60 62
0.045
0.01
0.032
0.01
0.022
0.05
0.019
NS
0.015
0.011
NS
0.015
NS
0.012
0.008
0.05
0.012
0.05
0.010
0.006
0.05
0.010
0.05
0.008
0.004
0.01
0.007
0.01
0.006
0.003
0.01
0.006
0.002
0.01
measurement of Dp and consequent calculation of Kf is not
possible in humans, so all information available so far are
necessarily derived from experimental work.
That Dp may be reduced by CEI has been extensively
documented experimentally [2, 5, 19]. In such studies CEI
therapy always reduced Dp while it tended to increase K. On
the basis of these experimental evidences the reduction in GFR
observed in our patients is likely a consequence of an effect of
enalapril of reducing Dp rather than Kf.
That enalapril could have lowered GFR by reducing glomer-
ular capillary pressure is also suggested by the observed reduc-
tion in mean systolic and diastolic BP of about 10 mm Hg. This
decrease in BP could account for a reduction of 5 mm Hg for
hydraulic pressure in glomerular capillaries induced by the CEI.
Moreover, according to the theoretical analysis, and consider-
ing an hypothetical reduction in Dp associated with enalapril
therapy equal to 5 mm Hg (approximately 50% of the observed
reduction in mean arterial pressure), mean calculated K did not
change significantly during the three studies (Table 3). This
would reinforce the concept that the fall in GFR induced by
enalapril in IgA nephropathy could result from a selective
reduction in glomerular capillary pressure.
This would be consistent with previous findings [201 that in
patients with unilateral renal artery stenosis CEI reduced the
tone of postglomerular arterioles, leading to a reduction in Dp.
On the same line, enalapril treatment in patients with renovas-
cular hypertension [21] has been reported to be associated with
loss of intrinsic glomerular vasoregulatory capacity with rela-
tively greater preservation of renal blood flow, while GFR fell
markedly both acutely and in the long term.
A second finding of the present study is that CEI therapy was
associated with a significant reduction in 24-hour urinary pro-
tein excretion, compared to the basal values, and that urinary
protein excretion rose back toward the baseline after enalapril
withdrawal. Consistent with the reduction in total urinary
protein excretion were data on albumin fractional clearance,
which was significantly reduced by enalapril and returned to
basal values after drug withdrawal.
To investigate whether this reduction in protein excretion
was related to an improvement of glomerular barrier function
induced by the drug, and not a consequence of changes in
tubular handling of filtered proteins, we measured the fractional
clearance of neutral dextrans of graded sizes. Enalapril did not
affect the sieving coefficient of small, relatively permeant dex-
tran molecules (< 42 A), but significantly reduced that of large
dextran macromolecules with radii from 56 to 62 A. This
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Fig. 3. Fractional clearance of neutral dextran molecules of graded
molecular size, measured before (El) and after enalapril treatment (I).
* P < 0.05, P < 0.01 as compared to Basal.
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Fig. 4. Fractional clearance of neutral dextran molecules of graded
molecular size, measured after enalapril treatment (U) and one month
after enalapril withdrawal (0). * P < 0.05, ** P < 0.01 as compared to
enalapril withdrawal.
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Table 3. Computed membrane parameters
Dp
mm Hg
Enalapril
Basal Enalapril withdrawal
Kr
mi/mm/mm Hg/I .73 m2
30
35
40
2.65 1.39
2.33 0,97 1.84 0.90a 2.41 1.04
1.78 0.69 1.41 0.66 1.82 0.71
u (A)
45
30
35
40
45
1.44 0.53 1.46 0.5
46.7 2.9
48.6 3.7 47.1 2.8 46.7 3.5
48.8 3.6 47.3 2.7 46.9 3.4
48.8 3.4 47.0 3.2
s 30
35
40
1.17 0.03
1.17 0.04 1.17 0.03 1.19 0.03
1.17 0.04 1.17 0.03 1.19 0.02
r*(1%) (A)
45
30
35
40
45
1.17 0.03 1.19 0.02
74,6 33b
78.2 4.3 74,4 2b 78.8 1.8
78.1 4.3 74,4 32b 78.7 1.7
78.1 4.3 78.6 1.6
Values are mean SD. Abbreviations are: Dp, transmembrane
pressure difference; K, ultrafiltration coefficient; u and s, a measure of
the mean and spread of pore radii distribution, respectively; r*,
calculated membrane pore parameter.
ap < 0.01 vs. Basal and vs. Enalapril withdrawal, for the same Dp
value
b P< 0.05 vs. Basal and P < 0.01 vs. Enalapril withdrawal, for all Dp
values
amelioration of the size-selective function can be responsible
for the reduction in glomerular filtration of circulating proteins
and in final urinary excretion.
Transglomerular passage of circulating macromolecules de-
pends on the intrinsic properties of the glomerular membrane
and on convective and diffusive forces resulting from glomeru-
lar hemodynamics [221. To further investigate whether the
reduced fractional clearance of large dextran molecules was
induced by a real improvement in glomerular membrane selec-
tive properties or by changes in glomerular hemodynamics, we
adopted a theoretical model of glornerular size-selective func-
tion that separates the effects of hemodynamic changes and
changes in intrinsic membrane permeability, on the filtration of
test macromolecules [16, 17]. This model represents the gb-
merular membrane as perforated by cylindrical pores having a
lognormal probability distribution of their radii. Enalapril treat-
ment had little effect on the mean (u) and the distribution (s) of
membrane pore radii, but significantly reduced the size of the
largest pores (Table 3). The radius of these non-restrictive
pores, which are responsible for the passage of circulating
macromolecules into the urinary space, was significantly re-
duced, as indicated by the calculated parameter r*(l%) (Table
3). Of note is the fact that the calculated change in membrane
pore radius associated with the CE! is unrelated to the assumed
value of Dp; thus, on a theoretical basis, the reduced filtration
of circulating test macromolecules could not result from an
hypothetical reduction in glomerular capillary pressure, associ-
ated with CE! treatment, but must derive from changes in
intrinsic membrane permselective properties.
The parallelism between changes in largest membrane pores
dimensions and mean fractional albumin clearance would sug-
gest that the two phenomena are related. Albumin is a protein
with a gel chromatographic radius of 36 A but, for its molecular
configuration and charge, albumin filtration seems to take place
only through largest membrane pores [23]. The fact that after
enalapril therapy fractional clearance of largest dextran mole-
cules (that is, 60 A, Table 2) and albumin (Fig. 2) were both
reduced to approximately 50% of basal values, and that a
comparable percentage increase was measured in these two
parameters after enalapril withdrawal, would suggest that the
observed size-selective changes can be sufficient to explain the
magnitude of changes in albumin fractional clearance. This
would suggest that CE! therapy has negligible influence on
charge selective properties of the glomerular membrane.
That in patients with IgA nephropathy enalapril directly
influences glomerular membrane functional properties is in
keeping with our previous experimental observation in MWF/
Ztm rats, a strain that spontaneously develops proteinuria and
glomerular structural damage [6]. Long-term enalapril therapy
protected these animals against the development of proteinuria
and an improvement was seen in glomerular size-selective
properties. The present results thus further demonstrate in
humans that the beneficial effect of enalapril on urinary protein
loss derives from a restoration of glomerular size-selectivity.
That enalapril has this particular action of restoring size-
selective properties of the glomerular barrier was recently
suggested by Morelli et al [5], who showed that in patients with
insulin-dependent diabetes mellitus enalapril therapy lowered
the transglomerular passage of neutral dextrans of graded sizes.
Beside the fact that enalapril improves glomerular size-
selectivity both in IgA nephropathy and in diabetic nephrop-
athy, it is of interest that this effect differs qualitatively in the
two conditions. In IgA nephropathy only the size of largest
non-selective pores is reduced, whereas in diabetes both small
and large pores became smaller. Thus enalapril may have
different effects on glomerular barrier size-selectivity in dif-
ferent diseases.
The mechanism(s) by which enalapril reduced the mean size
of the largest non-selective membrane pores in IgA nephrop-
athy must at the moment remain speculative. Since angiotensin
II increases the transglomerular passage of large neutral dex-
trans, as documented by studies in which it was infused to rats
and humans [12, 24], it can be postulated that in IgA nephrop-
athy enalapril may improve glomerular barrier size-selectivity
by preventing angiotensin II formation [25].
Regardless of its mechanisms, the beneficial effect of enala-
pril on glomerular barrier size-selectivity observed in this study
may open important perspective for preventing the progression
of IgA nephropathy to end-stage renal failure. The increased
traffic of plasma proteins across the glomerular capillary wall
may be one factor responsible for the long-term deterioration of
glomerular structure that eventually leads to glomerulosclerosis
[26]. Consistent with this are experimental findings that in
various models of renal disease progression, enalapril not only
lowers urinary protein excretion but also preserves the structure
of the glomerulus and prevent the development of glomerulo-
sclerosis [1, 2,6, 191. Whether in humans with IgA nephropathy
the long-term treatment with enalapril to reduce proteinuria will
also protect glomerular structural damage and retard the pro-
gressive nature of the disease is a possibility that merits an
appropriate controlled trial.
Our data also suggest that CE! may lower GFR in these
patients. Whether this also apply to other categories of renal
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disease or to patients treated with CEI for cardiac failure or
hypertension merits further investigation.
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